FOXO4-DRI

FOXO4-DRI

FOXO4-DRI is a synthetic peptide built in D-retro-inverso form: its amino acids are D-isomers assembled in reverse order. That arrangement roughly preserves the side-chain layout of the parent L-peptide while making the backbone resistant to proteases. The sequence is based on a region of the transcription factor FOXO4 that contacts the tumor suppressor p53, and it includes a cell-penetrating segment so that it can enter cells. At about 5.4 kDa, it is a large peptide for its class.

Product Specifications

• Product: FOXO4-DRI
• Amount: See available options above
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Chemical Profile

• Compound class: Synthetic D-retro-inverso peptide (FOXO4–p53 interaction disruptor)
• Molecular formula: C₂₂₈H₃₈₈N₈₆O₆₄
• Molecular weight: 5358.0 g/mol

What researchers study

Cellular senescence is a stable state of cell-cycle arrest triggered by DNA damage, oncogene activation, telomere shortening and other stresses. Senescent cells resist apoptosis and secrete a mix of inflammatory factors called the senescence-associated secretory phenotype (SASP). How they survive, and whether they can be selectively removed, are central questions in the biology of aging and of chemotherapy damage.

In 2017, a study in Cell reported that FOXO4 levels rise in senescent cells and that FOXO4 binds p53 in the nucleus, holding it in a state that favors arrest over cell death. FOXO4-DRI was designed to compete for that interaction. In the reported cell models, disrupting FOXO4–p53 binding led to p53 leaving the nucleus and to apoptosis selectively in senescent cells, a property described as senolytic.

Research areas include:

• Senescence models: irradiated or doxorubicin-treated human fibroblasts such as IMR90, compared with non-senescent controls.
• FOXO4–p53 biology: protein interaction, p53 localization and apoptosis assays.
• Rodent models: chemotherapy-induced senescence and accelerated-aging mouse strains, and senescent cell populations in specific tissues such as testicular Leydig cells and cartilage.
• Peptide chemistry: D-retro-inverso design and the stability of cell-penetrating peptides.

All published FOXO4-DRI work is preclinical, and results from cell and mouse models do not establish effects in humans.

Regulatory status

FOXO4-DRI is not approved by the FDA for any use and has not been approved as a drug anywhere. It is sold here as a research reagent only.

Quality & Documentation

Every batch of FOXO4-DRI is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Research overview

For a longer look at FOXO4-DRI, covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our FOXO4-DRI research overview. It is written as background reading, and every study it cites is linked to PubMed.

Selected literature

• Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID 28340339
• Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PMID 31959736

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.